Oxford Outcomes Research Study
Quick Overview: Oxford Outcomes is conducting a qualitative research study involving interviews with pheo/para patients in order to evaluate the clarity, relevance, and comprehensiveness of two questionnaires (one cancer specific and one pheo/para specific), and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.
Detailed Overview and Link:
Oxford Outcomes Inc
Molecular Insight Pharmaceuticals,
Inc. - Clinical Trial: Malignant Pheo, Paraganglioma
Quick Overview: This clinical trial benefits patients with certain types
of pheochromocytoma, paraganglioma or metastatic carcinoid tumors. Molecular
Insight Pharmaceuticals, Inc is located in Cambridge, MA, USA. The actual
study is being conducted at various location. Please see the link below for
more information about the clinical trial and locations.
Detailed Overview and Link:
Molecular Insight
Pharmaceuticals Clinical Trials
Cornell Medical Center - Study:
Focuses on patients with symptoms of pheochromocytoma but no evidence
of having the illness.
Quick Overview: This study benefits patients who have the severe symptoms
that are suggestive of pheochromocytoma but who don't have evidence to confirm
a diagnosis. Dr. Sam Mann of the New York Presbyterian Hospital in New York
is in charge of this study.
Detailed Overview and Link:
Cornell
Medical Center Study
